Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | WEE1 | P30291 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675938 | 0.88 | ALK (0.48) | ALKCHEK1WEE1PTK6ALDH1A1 | |
| SCHEMBL19022524 | 0.80 | ALDH1A1 (0.56) | CHEK1WEE1ALDH1A1TDP1KMT2A | |
| SCHEMBL674242 | 0.78 | ALDH1A1 (0.41) | ALKCHEK1WEE1ALDH1A1TDP1 | |
| SCHEMBL19022533 | 0.77 | KMT2A (0.56) | CHEK1WEE1ALDH1A1TDP1KMT2A | |
| SCHEMBL674678 | 0.77 | ALK (0.55) | ALKPTK6ERBB2KMT2AEGFR | |
| SCHEMBL675109 | 0.76 | PTPN1 (0.45) | ALKCHEK1WEE1ALDH1A1TDP1 | |
| SCHEMBL676124 | 0.75 | GRIN2D (0.42) | ALKCHEK1WEE1ALDH1A1TDP1 | |
| SCHEMBL24171431 | 0.75 | KMT2A (0.48) | CHEK1WEE1ALDH1A1TDP1KMT2A | |
| SCHEMBL24597963 | 0.74 | KMT2A (0.56) | CHEK1WEE1ALDH1A1TDP1KMT2A | |
| SCHEMBL24597989 | 0.74 | KMT2A (0.56) | CHEK1WEE1ALDH1A1TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895744-B2 | Alfa-carboline inhibitors of NPM-ALK, RET, and Bcr-Abl | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA (IT) | 2014-11-25 | — | — | US | disclosed |
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | UNIVERSITA' DEGLI STUDI DI MILANO - BICOCCA (IT) | 2011-11-17 | — | — | US | disclosed |
| EP-2161271-A1 | Alpha-carboline inhibitors of NMP-ALK, RET, and Bcr-Abl | Università Degli Studi Di Milano - Bicocca (IT) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281862-A1 | ALFA-CARBOLINE INHIBITORS OF NPM-ALK, RET, AND BCR-ABL | ALK, BCR, NPM1 | ALK 1/4885CHEK1 1744/4885WEE1 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.